• Histologically or cytologically confirmed pancreatic cancer

• Male or female participants who are at least 18 years of age on the day of signing in-formed consent

• Borderline resectable tumor (see table 1 for definitions of resectability)

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

• Ability to undergo surgery, radiotherapy and chemotherapy

• Leucocytes (WBC) ≥ 3.0 X 109/l

• Platelets ≥ 100X 109 /l

• Hemoglobin ≥ 6 mmol/l

• Renal function: E-GFR \> 50 ml/min

• Bilirubin \< 50 µmol/l or planned for biliary drainage

• A male participant must agree to use a contraception as detailed in Appendix 5 of this protocol during the treatment period and for at least 18 weeks after the last dose of study treatment and refrain from donating sperm during this period.

• A female participant is eligible to participate if she is not pregnant (see Appendix 5), not breastfeeding, or a woman of childbearing potential (WOCBP) who agrees to follow the contraceptive guidance during the treatment period and for at least 18 weeks after the last dose of study treatment.

• Written informed consent